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Summary 
The CD45  transmembrane protein tyrosine phosphatase plays an essential role in lymphocyte 
activation.  In humans, CD45 is composed of five isoforms that are generated by alternative splicing 
of three exons of a common precursor mRNA. Expression of the smallest molecular mass 180- 
kD CD45 isoform (CD45-O) results from splicing out of exons 4(A), 5(B),  and 6(C), which 
encode peptide  regions  near the NH2  terminus,  and is  regulated during T  cell maturation 
and activation.  Two monoclonal antibodies  (mAb),  UCHL1  (anti-CD45RO)  and A6  (anti- 
CD45RO-like),  were studied that selectively bind to murine transfectant cells expressing the 
human CD45-O isoform. The anti-CD45RO-like A6 mAb, but not the anti-CD45RO UCHL1 
mAb, also weakly reacted with transfectant cells expressing the human CD45 isoforms that contained 
exons 4 and 5(AB), or exon 5(B) encoded sequences. The structural basis of the antigen specificities 
of these two different human anti-CD45RO mAbs was investigated at the molecular level by 
using potential glycosylation-defective CD45-O isoform variants containing amino acid substitutions 
at the junction of exons 3 and 7. Replacement of the threonine residue at position 8 (last amino 
acid encoded in exon 3 and a putative O-linked carbohydrate anchorage site) by an alanine, completely 
abrogated the reactivity of the UCHL1 mAb, but did not affect that of the A6 mAb. Conversely, 
replacement of either the asparagine at position 174 or the serine at position 176 (the first two 
putative carbohydrate anchorage sites in exon 7) by alanine,  abrogated the reactivity of the A6 
mAb, but not that of the UCHL1  mAb. Both the UCHL1  and A6 epitopes were dependent 
on the presence of O-linked carbohydrates; and the UCHL1, but not the A6 epitope, was dependent 
on the presence of sialic acid. These results demonstrate a pivotal role for the amino acids encoded 
at the junction of exons 3 and 7 for the generation of glycosylation-related CD45RO epitopes 
that are expressed in a cell lineage- and activation-regulated fashion. 
T 
he transmembrane protein tyrosine phosphatase CD45 
is critically important for the activation of T cells through 
the TCR-CD3 complex (1-3), and may also be necessary for 
regulation of signaling via the Ig antigen receptor in B cells 
(4). Potential physiological substrates for CD45 include the 
tyrosine-phosphorylated negative regulatory sites of the pro- 
tein tyrosine kinases  p561ok and p56 fyn (5, 6).  Several mole- 
cules have been shown to associate  with CD45,  including 
intracellular and plasma membrane proteins, as well as cyto- 
skeletal components (7-10). Although recent reports suggest 
that the extracellular portion of CD45 is not essential for 
signaling through the TCR (11), both the structural and func- 
tional properties of CD45 support the possibility that its cy- 
toplasmic protein tyrosine phosphatase (PTPase) activity can 
be regulated by interaction of its extracellular region with 
specific ligand(s),  as it has been found for transmembrane 
receptors with tyrosine kinase activity. Furthermore, studies 
with anti-CD45 mAbs also demonstrate a role for CD45 in 
both early and late events of B and T  cell activation (1, 2), 
and regulation of CD45 PTPase activity (12), suggesting that 
the binding of specific mAbs on CD45 could mimic the in- 
teraction of this molecule with natural ligand(s). 
Human CD45 is composed of five isoforms that vary in 
their NH2-terminal region as a result of tissue-specific alter- 
native splicing.  Regulation of CD45 alternative splicing re- 
quires exon-specific cis-elements and negative regulatory trans- 
acting splicing factors (13, 14). The three alternatively used 
CD45 exons, exons 4,  5,  and 6,  encode peptide segments 
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been isolated that contain all three alternatively used exons 
(the ABC isoform), two of the three exons (the AB and BC 
isoforms), only one exon (the B isoform),  or lack all three 
alternatively used exons (the O isoform) (1, 2). Whereas CD45 
is abundantly expressed on most hematopoietic cells, specific 
isoforms  are  expressed  in  a  cell  lineage-  and  activation- 
dependent fashion (1, 2). Furthermore,  studies with geneti- 
cally engineered mice lacking expression of the higher mo- 
lecular weight isoforms suggest that different CD45 isoforms 
have distinct functions when expressed in various leukocyte 
lineages (15).  Because the cytoplasmic PTPase domains and 
the majority of the extracellular  domains are the same for 
all of the isoforms, the possibility exists that the alternative 
splicing regulated A, B, and C regions could mediate differen- 
tial interactions between CD45-1igands and particular CD45 
isoforms selectively expressed on certain cell types. However, 
the isoform selectively expressed in the majority of leuko- 
cytes, including  the memory T  cell subset which responds 
to recall  antigen  and provides help for the  synthesis of Ig 
by B cells,  is the  180-kD CD45-O  isoform.  This isoform 
lacks the NHz-terminal A, B, and C peptide segments, and 
thus contains the least amount of primary sequence informa- 
tion (1, 2). A unique feature of the CD45-O isoform is the 
juxtapositioning  of the sequences encoded by exons 3  and 
7 which generates the CD45RO  antigen  specificities  (16). 
To determine the molecular basis for the unique  structural 
properties of the CD45-O isoform, amino acid residues re- 
quired for CD45RO and CD45RO-like mAb binding were 
identified using a reversed genetic  approach. 
Materials  and Methods 
mAbs andlmmunofluorescence.  The anti-CD45RO UCHL1 and 
the anti-CD45  GAP8.3 mAb have been previously described (16) 
and were used as ascites fluid at a dilution  of 1/500.  The anti- 
CD45KO-like A6 mAb (17; Zymed Laboratories, Inc., South San 
Francisco, CA) was used at 5/zg/ml. MslgG1 mAb (Coulter Im- 
munology, HiaIeah, FL) was used as negative control. The expres- 
sion of CD45RO epitopes was analyzed by flow cytofluorography 
using  FITC-conjugated  goat anti-mouse as secondary Ab, on a 
Profile EPICS cell sorter  (both from Coulter Immunology). 
Plasmid Constructions and Cell Lines.  Construction of the five 
full-length  human  CD45  cDNAs,  fl-LCA.6  (CD45-ABC),  fl- 
LCA.338 (CD45-AB), fl-LCA.260 (CD45-BC), fl-I.CA.623 (CD45- 
B), and fl-LCA.1 (CD45-O) has been described previously (16). 
These  cDNAs were inserted  into  the cloning  site of a slightly 
modified version of the pcDbSRot296 expression plasmid (18), 
termed pSP65-SRc~.2. Amino acid substitution mutants were gener- 
ated by oligo-directed mutagenesis, and mutants  were confirmed 
by nucleotide sequencing. Amino acid substitutions  are given in 
Fig.  2 A.  Cell  lines expressing  the various CD45  isoforms or 
CD45-O mutants were established as described previously (16) using 
the murine pre-B lymphocyte cell line, 300-19, and the pSP65-SRoe2- 
CD45 expression plasmids. 
Purification of CD45-0 Glycoproteins, Radiolabeling, Glycosidase 
Treatments, and Immunoprecipitation.  CD45-O glycoproteins were 
purified from 300-19/CD45-O cells  by affinity chromatography with 
the anti-CD45  GAPS.3 mAb, and radioiodinated in solution with 
tetrachloro-diphenylglycoluril (Iodogen; Pierce Chemical Co., Rock- 
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ford, IL) as previously described (19). For neuraminidase digestion, 
the L2SI-labeled  purified CD45-O glycoproteins were incubated at 
37~  for 30 rain in PBS containing  20 mU/ml of neuraminidase 
from Clostridium  perfringes (Boehringer Mannheim, Mannheim, Ger- 
many). For O-glycosidase treatment, CD45-O proteins were boiled 
in 10 mM phosphate buffer, pH 7, containing 1% NP-40 and 0.1% 
SDS, and then were incubated at 37~  for 16 h with 35 mU/ml 
of O-Glycanase (Genzyme Inc., Cambridge,  MA) and 5 mU/ml 
of neuraminidase. For N-glycosidase treatment,  CD45-O proteins 
were boiled in 10 mM phosphate buffer, pH 7, containing 1% NP40, 
0.5% SDS, 8 mM EDTA, and 0.8% 2-ME, and then were incubated 
at 37~  for 16 h with 5 U/ml of endoglycosidase F/N-glycosidase 
F  (Boehringer  Mannheim).  For  immunoprecipitation,  equal 
amounts  of input  radioactivity  of lz5I-labeled proteins  were in- 
cubated with the mAb.  Immune  complexes were isolated using 
protein  G Sepharose (Pharmacia LKB, Uppsala, Sweden). 
Results and Discussion 
Alternative splicing of the human transmembrane protein 
tyrosine phosphatase CD45 results in the developmental and 
tissue-specific  expression of five different CD45 isoforms that 
differ from one another only in the NHz-terminal region (1, 
2). To understand better the molecular heterogeneity of the 
splicing-regulated  NH2-terminal  portion of human  CD45, 
epitopes were mapped that are selectively carried on the 180- 
kD CD45 glycoprotein (CD45-O). Two different mAbs were 
studied because of their selective reactivity by flow cytom- 
etry with transfected 300-19 pre-B mouse cells expressing the 
recombinant human CD45-O isoform (300-19/CD45-O): the 
anti-CD45RO UCHL1 mAb (20); and A6 mAb, herein desig- 
nated as anti-CD45RO-like  (17) (Fig.  1, panels 23 and 24, 
respectively).  Whereas  the  anti-CD45RO  UCHL1  mAb 
bound only to the 300-19/CD45RO cells, the anti-CD45KO- 
like A6 mAb weakly reacted with transfectant cells expressing 
human CD45 isoforms that contained sequences encoded by 
exons 4 and  5 (300-19/CD45-AB)  (55%  positive cells)  or 
by exon 5 (300-19/CD45-B) (22% positive cells) (Fig. 1, panels 
I2 and 20,  respectively), suggesting that  other CD45 iso- 
forms could weakly express the A6 epitope. Immunoprecipi- 
tation experiments using cell surface radioiodinated T  cells 
revealed that both the UCHL1 and A6 mAb precipitated only 
the 180-kD CD45 polypeptide (data not shown).  Previous 
studies demonstrated that the UCHL1 mAb is able to preclear 
all the 180-kD CD45 glycoproteins from PBLs, as recognized 
by a conventional anti-CD45 mAb, indicating the existence 
of only one 180-kD CD45 protein  (21).  Furthermore,  the 
A6 epitope was found to be present on a larger number of 
T cells than the UCHL1 epitope, and also to be coexpressed 
with the CD45RA 2H4 epitope on nonactivated "naive" T 
cells with inducer-suppresser  activity in vitro (17,  22,  and 
our unpublished  results).  Possibly, the A6 epitope is only 
weakly acquired on the CD45-AB and CD45-B isoforms, 
due to the sequence requirements for its generation (see below), 
making difficult its detection by immunoprecipitation  tech- 
niques. 
Carbohydrates  located  on  the NHz-terminal  portion  of 
the CD45 isoforms, including CD45-O, are involved in the 
generation  of restricted CD45 epitopes (23).  To analyze at 
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Figure  1.  Reactivity  of anti-CD45RO mAbs with mu- 
rine pre-B cells  expressing  individual  human  CD45 isoforms. 
300-19 pre-B mufine  cells  expressing  the distinct human  CD45 
isoforms, termed CD45-ABC, -AB, -BC, -B, and -O, or a 
control cell  line (vector  transfected  only)  were  incubated  with 
anti-CD45 GAP8.3, anti-CD45RO UCHL1, anti-CD45RO- 
like A6 mAbs, or Ig negative  control  mAb, and binding was 
measured by flow cytometry. 
the molecular level  the  epitopes  recognized by both  the 
UCHL1 and the A6 mAb, cDNAs were generated that con- 
tain site-directed mutations at the junction of exons 3 and 
7  that  potentially  encode  glycosylation-defective human 
CD45-O variants. The mutations generated are shown in Fig. 
2 A, and designated so as to indicate the wild-type residue 
mutated, the amino acid position, and the missense residue. 
CD45 cDNAs harboring the mutations were transfected into 
the mouse pre-B cell line 300-19, and CD45 biosynthesis and 
cell surface expression was monitored by using the conven- 
tional pan-anti-CD45 GAP8.3 mAb. Immunoprecipitation 
of lysates  from [35S]methionine-labeled  cells demonstrated 
that the distinct CD45-O variants were properly synthesized 
and expressed after transfection into the 300-19 cell line (data 
not shown). The reactivity of both the UCHL1 and the A6 
mAb with the panel of cells expressing the CD45-O variants 
was analyzed by flow cytometry (Fig. 2 B). Cells transfected 
with a CD45-O cDNA in which the threonine codon at po- 
sition 8 (putative O-linked carbohydrate anchorage site) was 
replaced by an alanine codon (TSA) did not bind the UCHL1 
mAb, but did bind the A6 mAb (Fig.  2 B, panels 15 and 
16, respectively). Conversely, cells containing CD45-O mu- 
tants in which either the asparagine residue at position 174 
(putative N-linked carbohydrate anchorage site) or the serine 
at position 176 (putative O-linked carbohydrate anchorage 
site) was replaced by an alanine residue (N174A and $176A, 
respectively), did not bind the A6 mAb (Fig.  2 B,  panels 
20 and 24, respectively), but were recognized by the UCHL1 
mAb (Fig. 2 B, panels 19 and 23, respectively). As expected, 
neither the UCHL1 nor the A6 mAb stained cells expressing 
the double mutant T8A-N174A (Fig. 2 B, panels 27 and 28, 
respectively). The other CD45-O  amino acid substitution 
mutations tested (T4A, S6A, and $186A) did not affect the 
recognition of the CD45-O isoform by either mAb (Fig.  2 
B). Biochemical confirmation of the carbohydrate dependence 
of the UCHL1 and A6 epitopes was obtained by analyzing 
the reactivity of both mAbs with glycosidase-digested, purified 
CD45-O proteins (Fig. 3). The UCHL1 epitope was destroyed 
by neuraminidase (cleaves sialic acid residues from carbohy- 
drate chains) and O-glycosidase (cleaves O-linked carbohy- 
drates) digestions (Fig. 3, lanes 6 and 7, respectively), in agree- 
ment with our earlier observations (23). In contrast, the A6 
epitope was resistant to neuraminidase treatment (Fig. 3, lane 
I0),  but was destroyed by O-glycosidase digestion (Fig.  3, 
lane II).  Both the UCHL1 and A6 epitopes were resistant 
to N-glycosidase (cleaves N-linked type carbohydrates) diges- 
tion (Fig. 3, lanes 8 and 12, respectively). Because our results 
demonstrate that the N-174 residue is required for genera- 
tion of the A6 epitope, the possibility exists that this residue 
is necessary for the anchorage of an O-linked carbohydrate 
molecule on the S-176 residue, or that N-174 itself is directly 
involved in the generation of the A6 epitope. In accordance 
with the proximity of residues T-8, N-174, and S-176 in the 
CD45-O isoform, mAb binding cross-inhibition experiments 
demonstrated that the UCHL1 and A6 epitopes overlap (17, 
and our unpublished results). These results demonstrate that 
specific amino acid residues in the sequence encoded by the 
junction of exons 3 and 7 are necessary for the selective an- 
chorage of O-linked carbohydrates, thus, generating different 
CD45RO  and CD45R.O-like antigen specificities. 
The important contribution of carbohydrates to the bio- 
chemical composition of mature CD45 glycoproteins has been 
documented (1). CD45 is recognized by mitogenic lectins, 
and CD45 carbohydrates are involved in the regulation of 
leukocyte functions (1). Herein, we have mapped the amino 
acid residues used for the isoform-specific anchorage of car- 
bohydrate molecules on the human CD45-O isoform. Our 
results demonstrate that highly regulated, isoform-specific 
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Figure  2.  Molecular mapping of glycosylation-related 
CD45RO epitopes. (A) The amino-terminal sequence of 
the human CD45-O isoform is given at the top of the 
figure using the standard one letter amino acid code, and 
below are listed the amino acid substitutions (dashes indi- 
cate identical amino adds). The numbering of the amino 
acids is according to Streuli et al. (25), with amino acids 
9-169 being derived from the alternatively used exons 4, 
5, and 6. Mutations are designated, using the one-letter 
code, with the wild-type amino acid, its residue number 
and the amino acid substitution. For example, the threo- 
nine residue at position 4 was mutated to an alanine res- 
idue, and is termed the T4A mutant.  (B) Reactivity of 
anti-CD45RO mAbs with murine pre-B cells expressing 
potential CD45-O glycosylation defective mutants. 300- 
19 pre-B murine cells expressing  wild type (wt) or amino 
acid substituted-CD45-O  mutants were incubated with 
the anti-CD45  GAP8.3, anti-CD45RO  UCHL1,  anti- 
CD45RO-like A6 mAbs, or Ig negative control mAb, 
and binding was measured by flow cytometry. 
glycosylation contributes to the generation of structural vari- 
ability within the distinct CD45 glycoproteins, even when 
no additional amino acid sequences are present (such as happens 
with  CD45-O),  in a manner that is ultimately directed by 
the  alternative splicing of the CD45  mRNA.  Comparison 
of the CD45  human,  murine,  and rat  sequences  contained 
at the junction of exons 3 and 7 (Fig. 4) reveals that the human 
residues T-8, N-174, and S-176 are not conserved in the mu- 
rine and rat CD45 counterparts,  suggesting that murine and 
rat CD45RO epitopes analogous to the human epitopes would 
be absent. In agreement with this hypothesis, neither anti- 
mouse nor anti-rat CD45RO  mAbs have been described so 
far. It should be also noted that both human UCHL1 and 
A6 carbohydrate-dependent  epitopes were acquired in the B 
cell mouse system here used,  as well as in NIH/3T3  cells 
(our unpublished results), indicating that both murine B cells 
and nonlymphoid cells contain  the machinery required  for 
such glycosylation events. In addition, differences have been 
found between the alternative splicing patterns of human and 
routine CD45 (14, 24). Thus, it appears that the regulation 
of the  variability present  on  the  NH2-terminal  portion  of 
CD45 molecules is extremely complex and different between 
species.  The understanding  of this variability at the molec- 
ular level will be helpful to elucidate the mechanisms by which 
CD45 PTPase activity and CD45-mediated activation events 
are regulated  in vivo. 
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Figure  4.  Alignment of the NHz-terminal amino acid sequences of the 
human, murine, and rat CD45-O isoform (1). The human residues T-8, 
N-174, and S-176, which  are involved in the  generation of CD45KO 
glycosylation-related epitopes, are indicated by arrows. Dots indicate the 
junctions between exons 3 and 7 in the distinct species; dashes indicate 
gaps in the sequence alignment. 
Figure  3.  Reactivity of anti-CD45RO  mAbs with glycosidase-treated 
CD45-O isoform purified proteins, mSI-labeled  CD45-O isoform protein 
untreated (lanes 1, 5, and 9), neuraminidase-treated (lanes 2, 6, and I0), 
O-glycosidase  plus neuraminidase-treated  (lanes 3, 7, and 11), or N-glyco- 
sidase-treated (lanes 4, 8, and I2) was immunoprecipitated by the UCHL1 
mAb (lanes 5-8) or the A6 mAb (lanes 9-12). Immune complexes were 
isolated and subjected  to SDS-6% PAGE  using reducing conditions. Lanes 
I-4 correspond to purified CD45-O proteins after the various treatments. 
Molecular mass standards in kilodahons (kD) are shown at the left. 
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